MarketBeat
06 Nov 2026, 05:15 UTC · 3h ago
CryoPort Q3 Earnings Call Highlights
Impact · against what's priced in
CryoPort's raised 2026 revenue outlook and second consecutive quarter of positive adjusted EBITDA provide a positive catalyst for the stock. While the shift of four regulatory filings into 2027 is a headwind, the immediate growth in life sciences services and upcoming FDA decisions for Arcellx and Capricor offer near-term upside.
- CYRX+0.50
No priced-in read yet
- In context
The company raised its FY2026 revenue outlook to $197M-$199M and reported a $1.8M YoY improvement in adjusted EBITDA, though this is partially offset by four regulatory applications shifting from 2026 into 2027.
Read from the article alone
